February 19th 2025

In partnership with

The Daily Innovation Newsletter

Enjoying this newsletter? Know someone who would too? Forward this email to them!

February 19th 2025

⚡️ Energy

Scientists at France's CEA have set a new milestone in fusion research by maintaining a stable plasma reaction for 1,337 seconds (over 22 minutes) in the WEST Tokamak reactor. This achievement surpasses China's recent record and advances efforts to sustain high-temperature plasma for longer periods—crucial for developing commercial fusion energy. The findings will contribute to the ITER project, aiming to make fusion a viable clean energy source. Future experiments will push for even longer and hotter reactions.

🌎 Environment

Scientists at the University of Washington have developed a sustainable material by combining used coffee grounds with Reishi mushroom spores to create a 3D-printable paste. Published in 3D Printing and Additive Manufacturing, the study shows that the fungal mycelium binds the coffee grounds into a resilient, water-resistant, and fully compostable material. This innovation could replace Styrofoam in packaging and small-scale manufacturing, offering an eco-friendly alternative to plastic waste.

💉 Biotechnology

Scientists at the University of Queensland have developed a method to introduce genetic material into plants via their roots using nanoparticle technology, potentially revolutionizing crop improvement. The research shows that coated nanoparticles can penetrate rigid plant cell walls to deliver synthetic mRNA, which then spreads through the plant. This technique, published in Nature Plants, could accelerate the development of improved crop varieties without traditional breeding or genetic modification, offering a faster and more flexible approach to enhancing food quality and yield.

💊 Healthcare

Scientists from Queen Mary University of London, Barts Hospital, and Cambridge University Hospital have created a specialized CT scan that detects tiny aldosterone-producing nodules in the adrenal glands, a hidden cause of high blood pressure. Published in Nature Medicine, the scan uses a radioactive dye to pinpoint the affected gland, allowing for targeted surgery that could cure hypertension in some patients. This breakthrough offers a faster, less invasive alternative to traditional diagnostic tests, potentially transforming hypertension treatment worldwide.

A study led by Mount Sinai researchers has found that sotagliflozin, a newly approved SGLT inhibitor for diabetes and kidney disease, is the first in its class to significantly lower heart attack and stroke risk. Published in The Lancet Diabetes & Endocrinology, the trial of 10,584 patients showed a 23% reduction in major cardiovascular events. Unlike other SGLT2 inhibitors, sotagliflozin blocks both SGLT1 and SGLT2, offering broader cardiovascular benefits. This breakthrough could expand its use in high-risk patients worldwide.

Scientists at the University of Michigan have created a sponge-like implant that attracts diseased immune cells, allowing researchers to study and treat multiple sclerosis (MS) in mice. Published in PNAS, the study used nanoparticle-based therapy to block inflammatory signals, preventing disease onset when administered early and reducing symptoms by half when given later. This breakthrough could lead to better treatments for primary progressive MS, the most aggressive form of the disease.

Stay up-to-date with AI

The Rundown is the most trusted AI newsletter in the world, with 1,000,000+ readers and exclusive interviews with AI leaders like Mark Zuckerberg, Demis Hassibis, Mustafa Suleyman, and more.

Their expert research team spends all day learning what’s new in AI and talking with industry experts, then distills the most important developments into one free email every morning.

Plus, complete the quiz after signing up and they’ll recommend the best AI tools, guides, and courses – tailored to your needs.

That’s all for today, please reply to this email if you have any comments or feedback, we’d love to hear from you about what we can do better!

Have you enjoyed this email? Make sure to share it with your friends and colleagues.

Thanks for reading!